Pirfenidone

CHEMBL1256391 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
185.2 g/mol
LogP
1.9
Phase
4

Used to slow the progression of idiopathic pulmonary fibrosis, a serious lung disease that causes the lung tissue to become scarred and stiff, making it increasingly difficult to breathe. It works by reducing inflammation and the build-up of scar tissue in the lungs.

Молекулярная масса

185,2200 g/mol

LogP

1,90

TPSA

20,30 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1ccc(=O)n(-c2ccccc2)c1

InChI

InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

Molecular Formula

C12H11NO

HBD / HBA

- / 1

Вращаемые Связи

1

Тяжёлые Атомы

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Used to slow the progression of idiopathic pulmonary fibrosis, a serious lung disease that causes the lung tissue to become scarred and stiff, making it increasingly difficult to breathe. It works by reducing inflammation and the build-up of scar tissue in the lungs.

Yes, Pirfenidone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1256391. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 40632. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.